BioNTech and Fosun: Agreement to supply mRNA COVID-19 vaccines to China

BioNTech and Fosun: Agreement to supply mRNA COVID-19 vaccines to China

BioNTech and Fosun: Agreement to supply mRNA COVID-19 vaccines to China. The supply agreement reflects the joint commitment of the two companies. Both parties have taken an important step towards achieving the accessibility and affordability of high-quality COVID-19 vaccines in China; Up to now, the mRNA COVID-19 vaccine BNT162b2 is in phase II in Jiangsu Province, China Clinical Trials;

“We would like to thank the Chinese government and the State Food and Drug Administration for their support and trust in our vaccine research and development work to help deal with the global epidemic threat.” said Ugur Sahin, MD, CEO and co-founder of BioNTech. “The joint efforts with Fosun Pharma on vaccine development this time prove the importance of global cooperation, which is also an important part of our strategic plan to supply vaccines on a global scale. This supply agreement is aimed at us for the world This is an important step towards the common goal of bringing safe and effective vaccines to the people.”

Wu Yifang, Chairman and CEO of Fosun Pharma, said, “Since the outbreak of the COVID-19 epidemic, we and BioNTech have always worked closely together in the joint prevention and control mechanism of the State Council, especially the State Drug Administration, the National Health Commission, the Ministry of Science and Technology and other relevant authorities. With the care and support of BNT162b2 mRNA, the clinical research and development of the new coronavirus nucleic acid vaccine in China is rapidly promoted, and the vaccine is actively promoted in China on the premise of ensuring the safety and effectiveness of the vaccine. The BNT162b2 mRNA new coronavirus nucleic acid vaccine is a success of international research and development cooperation Exemplary. I am very pleased to reach a future supply agreement with BioNTech in China. This is an important step for Fosun Pharma and BioNTech to strive to achieve the availability and affordability of high-quality COVID-19 vaccines in China.”

On March 13, 2020, BioNTech and Fosun Pharma reached a strategic cooperation agreement. The two parties will jointly develop and commercialize vaccine products against the new coronavirus based on BioNTech’s proprietary mRNA technology platform in mainland China, Hong Kong, Macao and Taiwan.

The two parties have launched a domestic phase II clinical trial of the candidate mRNA COVID-19 nucleic acid vaccine BNT162b2 in Taizhou and Lianshui, Jiangsu, China on November 24, 2020. The trial plans to recruit 960 healthy subjects, aged 18 to 85 years old. Evaluate the safety and immunogenicity of the candidate vaccine to support the future market application of the vaccine in China.

About BioNTech

BioNTech is a new generation immunotherapy company dedicated to pioneering the development of new therapeutic drugs for tumors and other critical illnesses. The company explored a large number of computing research and development and therapeutic drug platforms to rapidly develop new biopharmaceutical products. Its wide range of tumor candidates include individualized and mRNA-based off-the-shelf therapeutic drugs, innovative chimeric antigen receptor T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies, and small molecule drugs.

With deep expertise in the field of mRNA vaccine research and development and in-house production capabilities, BioNTech and its partners are continuously developing a variety of mRNA vaccine candidates for a series of infectious diseases and tumor product lines.

BioNTech has established extensive relationships with many pharmaceutical partners around the world, including Genmab, Sanofi, Bayer Animal Health, Roche Group members Genentech, Genevant, Reginaron Pharmaceuticals, Fosun Pharma and Pfizer.

About Fosun Pharma

Fosun Pharma takes innovative R&D as its core driving factor, continues to improve the drug R&D system of “combination of generics and innovations”, and builds an international R&D platform for small molecule innovative drugs, high-value generic drugs, biological drugs, and cell therapy.

Facing the future, under the guidance of the “4IN” (Innovation Innovation, Internationalization, Integration, Intelligent Intelligentization) strategy, Fosun Pharma Group adheres to the brand concept of “Continuous Innovation and Enjoying Health” and is committed to becoming a global mainstream medical A leading company in the health market.

Disclaimer of medicaltrend.org